The cytokine system of bone tissue;Knoglevævets cytokinsystem

Ugeskrift for Laeger

Volumn 167, Issue 8, 2005, Pages 874-878

  Stilgren, Lis Saalbach ^b   Abrahamsen, Bo ^b   Abdallah, Basem M ^b   Jørgensen, Niklas Rye ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CYTOKINE; GROWTH FACTOR; IMMUNOGLOBULIN KAPPA CHAIN; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 6; OSTEOPROTEGERIN; SOMATOMEDIN B; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CELL RECEPTOR; CYTOKINE RECEPTOR; GLYCOPROTEIN; INTERLEUKIN DERIVATIVE; TNFRSF11B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

BONE DISEASE; BONE TISSUE; BONE TURNOVER; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; HUMAN; METABOLIC DISORDER; OSSIFICATION; OSTEOLYSIS; REVIEW; BONE; BONE REMODELING; DRUG EFFECT; IMMUNOLOGY; METABOLIC BONE DISEASE; METABOLISM; OSTEOBLAST; OSTEOCLAST; PHYSIOLOGY;

BONE AND BONES; BONE DISEASES, METABOLIC; BONE REMODELING; BONE RESORPTION; CYTOKINES; GLYCOPROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; INTERLEUKINS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; RECEPTORS, CYTOKINE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 14844318026     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Charles P, Elliott MJ, Davis D et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
2. Olney RC. Regulation of bone mass by growth hormone. Med Pediatr Oncol 2003;41:228-234.
3. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997;18:801-31.
4. McCarthy TL, Centrella M, Canalis E. Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calcarial cultures. Endocrinology 1989;124:301-9.
5. Laron Z, Klinger B. Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). Eur J Endocrinol 1998;138;176-80.
6. Powell-Braxton L, Hollingshead P, Warburton C et al. IGF-I is required for normal embryonic growth in mice. Genes Dev 1993;7:2609-17.
7. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-53.
8. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
9. O'Brien EA, Williams JH, Marshall MJ. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem Biophys Res Commun 2000;274:281-90.
10. Jimi E, Akiyama S, Tsurukai T et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 1999;163:434-42.
11. Juji T, Hertz M, Aoki K et al. A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders. J Bone Miner Metab 2002;20:266-8.
12. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602.
13. Tsuda E, Goto M, Mochizuki S et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137-42.
14. Yun TJ, Chaudhary PM, Shu GL et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 1998;161:6113-21.
15. Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12: 1260-8.
16. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
17. Kostenuik PJ, Bolon B, Morony S et al. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 2004;34:656-64.
18. Stilgren LS, Rettmer E, Eriksen EF et al. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone 2004;35:256-65.
19. Sehett G, Kiechl S, Redlich K et al. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004;291:1108-13.
20. König A, Mühlbauer RC, Fleisch H. Tumor necrosis factor alpha and interleukin-1 stimulate bone resorption in vivo as measured by urinary 3H-tetra-cycline excretion from prelabeled mice. J Bone Miner Res 1988;3:621-7.
21. Ralston SH. Analysis of gene expression in human bone biopsies by polymerase chain reaction: evidence for enhanced cytokine expression in postmenopausal osteoporosis. J Bone Miner Res 1994;9:883-90.
22. Pacifici R, Brown C, Puscheck E et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA 1991;88:5134-8.
23. Sabatini M, Boyce B, Aufdemorte T et al. Infusions of recombinant human interleukin 1 alpha and 1 beta cause hypercalcemia in normal mice. Proc Natl Acad Sci USA 1988;85:5235-9.
24. Stashenko P, Dewhirst FE, Rooney RL et al. Interleukin-1 beta is a potent inhibitor of bone formation in vitro. J Bone Miner Res 1987;2:559-65.
25. Abrahamsen B, Shalhoub V, Larson EK et al. Cytokine RNA levels in transiliac bone biopsies from healthy early postmenopausal women. Bone 2000;26:137-45.
26. Fagiolo U, Cossarizza A, Scala E et al. Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol 1993;23:2375-8.
27. Khosla S, Peterson JM, Egan K et al. Circulating cytokine levels in osteoporotic and normal women. J Clin Endocrinol Metab 1994;79:707-11.
28. Palmqvist P, Persson E, Conaway HH et al. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 2002;169:3353-62.
29. Abrahamsen B, Bonnevie-Nielsen V, Ebbesen EN et al. Cytokines and bone loss in a 5-year longitudinal study - hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. J Bone Miner Res 2000;15:1545-54.
30. Weitzmann MN, Cenci S, Rifas L et al. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood 2000;96:1873-8.
31. Urist MR. Bone: formation by autoinduction. Science 1965;150:893-9.
32. Wozney JM. Overview of bone morphogenetic proteins. Spine 2002;27:S2-8.
33. Wozney JM, Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop 1998;26-37.
34. Jorgensen NR, Henriksen Z, Sorensen OH et al. Dexamethasone, BMP-2, and 1,25-dihydroxyvitamin D enhance a more differentiated osteoblast phenotype: validation of an in vitro model for human bone marrow-derived primary osteoblasts. Steroids 2004;69:219-26.
35. Rosier RN, O'Keefe RJ, Hicks DG. The potential role of transforming growth factor beta in fracture healing. Clin Orthop 1998;S294-300.
36. Geiser AG, Zeng QQ, Sato M et al. Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-betal gene. Bone 1998;23:87-93.
37. Bekker PJ, Holloway D, Nakanishi A et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001;16:348-60.
38. Hermann J, Mueller T, Fahrleitner A et al. Early onset and effective inhibition of bone resorption in patients with rheumatoid arthritis treated with the tumour necrosis factor alpha antibody infliximab. Clin Exp Rheumatol 2003; 21:473-6.
39. Ghiron LJ, Thompson JL, Holloway L et al. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res 1995;10:1844-52.
40. Boonen S, Rosen C, Bouillon R et al. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J Clin Endocrinol Metab 2002;87:1593-9.